- Talin BARISANI-ASENBAUER, MD
- Andreas BERGTHALER, DVM
- Keiryn L. BENNETT, PhD
- Angelika BERGER, MD
- Michael BERGMANN, MD
- Christoph BINDER, MD, PhD
- Barbara BOHLE, PhD
- Kaan BOZTUG, MD
- Heimo BREITENEDER, PhD
- Michael DUCHENE, PhD
- Adelheid ELBE-BÜRGER, PhD
- Wilfried ELLMEIER, PhD
- Michelle EPSTEIN, MD
- Sabine FLICKER, PhD
- Christina FORSTNER, MD
- Elisabeth FÖRSTER-WALDL, MD
- Hildegard GREINIX, MD
- Franz X. HEINZ, PhD
- Kurt HERKNER, MD
- Erhard HOFER, PhD
- Johannes HUPPA, PhD
- Erika JENSEN-JAROLIM, MD
- Renate KAIN, MD
- Reinhard KIRNBAUER, MD
- Alexander KIRSCHNER, PhD
- Reinhard KLEIN, PhD
- Sylvia KNAPP, MD, PhD
- Herwig KOLLARITSCH, MD
- Karl KUCHLER, PhD
- Vladimir LEKSA, PhD
- Birgit LINHART, PhD
- Yan MA, MD
- Diana MECHTCHERIAKOVA, PhD
- Verena NIEDERBERGER-LEPPIN, MD
- Rainer OBERBAUER, PhD
- Rudolf OEHLER, PhD
- Winfried F. PICKL, MD
- Christian RADAUER, PhD
- Andy REES, MD
- Marcus SÄEMANN, MD
- Gernot SCHABBAUER, PhD
- Wolfgang SCHREINER, PhD
- Peter STEINBERGER, PhD
- Günter STEINER, PhD
- Christoph STEININGER, PhD
- Karin STIASNY, PhD
- Hannes STOCKINGER, PhD
- Herbert STROBL, MD
- Susanne VRTALA, PhD
- Julia WALOCHNIK, PhD
- Thomas WEICHHART, PhD
- Thomas WEKERLE, MD
- Ursula WIEDERMANN-SCHMIDT, MD, PhD
- Gerhard J. ZLABINGER, MD
Marcus Säemann, MD
Associate Professor of Internal Medicine III
Division of Nephrology and Dialysis
Department of Internal Medicine III
Währinger Gürtel 18-20
1090 Vienna, Austria
Phone: +43 (0)1 40400 - 55930
FAX: +43 (0)1 40400 - 77900
E-mail: marcus.saemann@meduniwien.ac.at
Research Interest
Pro-inflammatory effects of HDL in chronic renal disease, proteomic composition of uremic HDL, molecular mechanism of HDL dysfunctions.
High-density Lipoprotein and inflammation in chronic renal disease
One of our central research interests is the characterization of High-density lipoprotein (HDL) quality in chronic renal disease at the molecular and functional level.
Cardiovascular mortality is highly prevalent in chronic kidney disease (CKD) and end-stage renal disease (ESRD), which is centrally driven by a state of chronic inflammation in these patients.
HDL usually possesses strong anti-atherogenic and anti-inflammatory properties that are defective in ESRD patients.
Our work focuses on identifying molecular mechanisms responsible for the conversion of HDL into a dysfunctional, pro-inflammatory particle in uremic conditions.
By proteomic profiling we identify disease-specific remodeling to characterize a distinct HDL profile which can be linked to functional impairments in CKD and ESRD.
Currently, we are interested in the molecular properties of HDL after renal transplantation to determine if impaired HDL quality can be restored with recovery of renal function.
Our experimental approaches include proteomic analysis, a wide spectrum of immunological analytical methods and cell culture techniques.
Selected References
Marsche G, Säemann MD, Heinemann A, Holzer M. Pharmacol Ther. Inflammation alters HDL composition and function: implications for HDL-raising therapies. 2013 Mar;137(3):341-51
Weichhart T, Kopecky C, Kubicek M, Haidinger M, Döller D, Katholnig K, Suarna C, Eller P, Tölle M, Gerner C, Zlabinger GJ, van der Giet M, Hörl WH, Stocker R, Säemann MD. Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol. 2012 May;23(5):934-47.
Featured
